Global Neurological Biomarkers Market to Grow 15.48% by 2020 - Increasing Focus Toward Drug Discovery Applications - Research and Markets

DUBLIN, September 20, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Neurological Biomarkers Market 2016-2020" report to their offering.

The report forecasts the global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020.

Integrated biology approach will be the key focus area and a key trend for market growth. Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area.

According to the report, one of the key drivers for market growth will be increasing focus toward drug discovery applications. Close to 1% of medications in the biomarker discovery and development pipeline achieve the commercial success. The rate of failure cases is too high, and very frequently drug candidates fail in the late development phase. This has led to the evolution of alternative biomarker-based techniques by contract research organizations and manufacturers.

Further, the report states that unmet market needs will be a challenge for the market. The inability to give convincing proof regarding the clinical and financial advantages of introducing new biomarker-based diagnosis methods are recognized as the main challenge for moderate uptake of new biomarkers. Genuine limitations, such as reproduction of positive clinical trial result, the absence of early pre-analytical examinations, the absence of autonomous check of results, and failure of investigators to assess whether the use of the biomarker would improve clinical practice to the benefit of neuro patients are hindering diagnostic neurological biomarker validation. Innovative evaluation of fluid-based proteomics enables biomarkers identification as indicators of the onset of neurological disease have been complex and incurs high research cost.

Key vendors:

• Myriad RBM
• Proteome Sciences
• QIAGEN
• Thermo Fisher Scientific

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by indication

PART 07: Market segmentation by application

PART 08: Market segmentation by services

PART 09: Market segmentation by end-user

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

PART 17: Key vendor analysis

PART 18: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/rvzrb2/global

Related Topics: Biomarkers

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]